I. COMMENCED TRADING IN FEBRUARY
 
Company (Symbol)# Date Filed Date Comm. Shares/Units (M) Price SharesOut (M)@ Lead, OtherUnderwriters Gross (US$M) Post-OfferingMarket Cap (M)%
 
INITIAL OFFERINGS
 
Bioheart Inc. (BHRT)1 2/13/07 2/20/08 1.1S $5.25 14.4 Dawson James Sec. $5.8 $75.6
Total: $5.8MNumber of IPOs in February: 1.
Average value of February IPOs: $5.8Number of IPOs in 2008: 1
Total raised in IPOs in 2008: $5.8MAverage value of IPOs in 2008: $5.8M
 
FOLLOW-ON OFFERINGS
 
Acorda Therapeutics Inc. (ACOR)2 2/6/08 2/13/08 3.795S $21.50 32.3 JP Morgan Securities
Deutsche Bank Sec. (co-lead)
Lazard Capital Markets
Piper Jaffray
Cowen & Co.
Friedman Billings Ramsey
$81.6 $694.45
 
Opexa Therapeutics Inc. (OPXA)3 2/14/08 2/14/08 3.5S and 4W $2
$0.15
10.2 MDB Capital Group LLC
GunnAllen Financial
(co-lead)
$7.6 $20.4
 
Rigel Pharmaceuticals
Inc. (RIGL)
1/24/08 2/1/08 5S $27 36 Credit Suisse Sec.
Thomas Weisel Partners
Jefferies & Co. Inc.
Oppenheimer & Co.
$135 $972
 
Vertex Pharmaceuticals
Inc. (VRTX)4
2/12/08 2/13/08 6.9S and Notes $17.14 139.8 Merrill Lynch & Co.
Goldman, Sachs & Co.
Morgan StanleyJP Morgan
$405.8 $2,396.17
 
OVERALLOTMENT OPTIONS
 
Orexigen Therapeutics Inc.
(OREX)5
1/7/08 2/7/08 0.326S $11 34.3 Merrill Lynch & Co.
Leerink Swann (co-lead)
JMP Securities LLC
Lazard Capital Markets
Canaccord Adams Inc.
Natixis Bleichroeder
$3.6 $377.3
Total: $633.6MNumber of follow-on offerings in February: 4
Average value of February follow-ons: $158.4MNumber of follow-on offerings in 2008: 9
Total raised in follow-ons in 2008: $1,047.2MAverage value of follow-ons in 2008: $116.4M
Notes:# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
@ This column reflects the shares outstanding following the offering, when disclosed.% Market capitalization is calculated based on the offering price.
Currency conversions are based on exchange rates at the time of the deal.1 Bioheart's overallotment option: 165,000 shares.
2 Acorda stockholders also are offering 83,000 shares. Includes overallotment option: 495,000 shares. 3 Opexa sold 3.5M shares at $2 each and 3.5M Series E warrants for 15 cents each, plus 525,000 Series E warrants for an overallotment option.
4 Vertex's financing consists of the sale of 6.9M shares and a separate offering of $287.5M in 4.75% convertible senior subordinated notes due in 2013. 5 Orexigen sold a total of 7.3M shares and raised $80.6M.
 
II. FILED AND PENDING
 
Company(Symbol/
Proposed Symbol)#*
DateFiled Shares/Units
(M)
PriceRange SharesOut
(M)@
Lead, OtherUnderwriters Value(M)
 
INITIAL OFFERINGS
 
Aegerion Pharmaceuticals Inc. (AEGR) 11/21/07 N/A N/A N/A Piper Jaffray
Thomas Weisel Partners (co-lead)
Lazard Capital Markets
Collins Stewart LLC
$86
 
Anacor Pharmaceuticals Inc. (ANAC) 8/31/07 N/A N/A N/A Morgan Stanley & Co. Inc.
Cowen & Co. LLC (co-lead)Pacific Growth Equities LLC
Needham & Co. LLC
$57.5
 
Bayhill Therapeutics Inc. (BHTX) 1/9/08 N/A N/A N/A Pacific Growth Equities LLC
Lazard Capital MarketsMerriman Curhan Ford & Co.
Punk, Ziegel & Co.
$86
 
Chemocentryx Inc. (CCXI) 11/12/07 N/A N/A N/A Credit Suisse Securities LLC
Cowen and Co.Leerink Swann
Lazard Capital Markets
$57.5
 
Elixir Pharmaceuticals Inc. (ELXR) 9/24/07 5S $14-$16 143.5 Credit Suisse Securities LLC
Pacific Growth EquitiesLeerink Swann LLC
$75
 
Insys
TherapeuticsInc. (INRX)
8/20/07 N/A N/A N/A Banc of America Securities
UBS Investment Bank (co-lead)JMP Securities
Natixis Bleichroeder
$86.25
 
MolMed SpA
(Italy)1
2/20/08 26.1S €2.15-
€2.75
N/A N/A €63.9
($94.6)
 
MonoSol Rx Inc.
(MSRX)
5/14/07 4S $16-$18 15 Cowen and Co.
CIBC World MarketsSusquehanna Financial
$68
 
Omeros Corp.
(OMER)
1/10/08 N/A N/A N/A Deutsche Bank Securities
Pacific Growth EquitiesLeerink Swann LLC
Needham & Co. LLC
$115
 
Peplin Inc.
(PLIN)
8/10/07 N/A N/A N/A Merrill Lynch & Co.
Cowen & Co. LLCThomas Weisel Partners
Leerink Swann & Co.Merrill Lynch International
Wilson HTM
$75
 
Phenomix Corp.
(PHMX)
1/28/08 N/A N/A N/A Morgan Stanley
Credit Suisse (co-lead)Oppenheimer & Co.
Pacific Growth Equities
$86
 
Prometheus
Laboratories Inc.
12/19/07 N/A N/A N/A Goldman Sachs & Co.
Credit Suisse (co-lead)
$100
 
RXi
PharmaceuticalsCorp. (RXIP;
unit of CytRx Corp.)
10/30/07 10.8S N/A N/A N/A N/A
 
Talecris Biothera-peutics Holdings Corp. (TLCR) 7/30/07 N/A N/A N/A Morgan Stanley
Goldman Sachs & Co.J.P. Morgan
$1B
 
Xanodyne Pharmaceuticals Inc. (XANO) 11/9/07 N/A N/A N/A Morgan Stanley
Deutsche Bank (co-lead)RBC Capital Markets
Natexis Bleichroeder
$86.25
 
XDx Inc. (XDXI) 10/24/07 N/A N/A N/A J.P. Morgan Securities Inc.
Morgan Stanley & Co. (co-lead)Piper Jaffray & Co.
JMP Securities LLC
$86.3
 
FOLLOW-ON OFFERINGS
 
Akela Pharma Inc. (Canada; TSX:AKL) 2/25/08 7.5U $1.20 N/A Jennings Capital Inc.
Desjardins Securities Inc.
$9
 
Biodel Inc. (BIOD)2 1/16/08 3.26S $23.68 23.5 Morgan Stanley & Co. Inc.
JP Morgan Securities Inc.Leerink Swann LLC
Natixis Bleichroeder Inc.
$77.2
 
Genoptix Inc. (GXDX) 2/14/08 4.2S $30.50 N/A Lehman Brothers Inc.
Banc of America SecuritiesUBS Investment Bank
Cowen and Co. LLC
$128.1
 
WITHDRAWN AND POSTPONED
 
Company (Symbol)# Date Filed/ Date Pulled Shares/ Units  (M) Price Range Shares Out  (M)@ Lead, Other Underwriters Value (M)

Archemix Corp. (ARCH)3 7/25/07
2/8/08
N/A N/A N/A Banc of America Securities
Bear, Stearns & Co. Inc.Cowen and Co.
$69
 
Biolex Inc. (BLEX)4 8/14/07
2/4/08
N/A N/A N/A Lehman Brothers Inc.
Deutsche Bank (co-lead)Leerink Swann & Co. Inc.
$70
 
Light Sciences Oncology Inc. (LSON)5 4/21/06
2/11/08
5.25S $14-$16 18.5 Cowen & Co.
Wachovia Securities (co-lead)Jefferies & Co.
Thomas Weisel Partners
$78.75

Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed.The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing.
N/A = Not available, applicable or reported. TSX = Toronto Stock Exchange.
1 MolMed plans to list its shares on the Mercato Telematico Azionario.
2 Biodel's overallotment: 550,000 shares.
3 Archemix withdrew its proposed IPO, citing unfavorable market conditions.
4 Biolex withdrew its proposed IPO, citing unfavorable market conditions.
5 Light Sciences withdrew its proposed IPO, citing unfavorable market conditions.